Think a Democrat-led House will only focus on drug pricing proposals? Sorry, pharma. Think againAllbiopro2018-11-08T09:16:45+09:0011월 8th, 2018|
https://www.fiercebiotech.com/biotech/mirum-scoops-120m-to-take-ex-shire-drug-into-phase-3Allbiopro2018-11-08T09:16:17+09:0011월 8th, 2018|
https://www.fiercebiotech.com/biotech/sitc-merck-highlights-new-lag-3-and-tigit-dataAllbiopro2018-11-08T09:15:50+09:0011월 8th, 2018|
Bye bye biosimilars: Big Pharma’s imminent exit in sight, says expertAllbiopro2018-11-08T09:14:57+09:0011월 8th, 2018|
Catalent pumping $200m into biomanufacturing expansionsAllbiopro2018-11-08T09:14:30+09:0011월 8th, 2018|
Material could give dialysis patients the freedom to moveAllbiopro2018-11-08T09:13:12+09:0011월 8th, 2018|
Abzena invests in expansion of biotherapeutics and makes executive appointmentAllbiopro2018-11-08T09:12:45+09:0011월 8th, 2018|
Construction of New Research, Development and Manufacturing Facilities for Drugs Using Innovative Modalities/Technologies Including Antibodies and Cell Therapies Announced by AstellasAllbiopro2018-11-07T08:49:21+09:0011월 7th, 2018|
Sandoz Decides Not To Pursue US Biosimilar Rituximab; Will Focus On Robust Biosimilar Portfolio For Unmet Access And Sustainability NeedsAllbiopro2018-11-07T08:48:24+09:0011월 7th, 2018|
AbbVie Announces VENCLYXTO® (venetoclax) Plus Rituximab Receives European Commission ApprovalAllbiopro2018-11-07T08:47:54+09:0011월 7th, 2018|
Achaogen Initiates Strategic Review, Plans Significant Cut to Operating ExpensesAllbiopro2018-11-07T08:47:26+09:0011월 7th, 2018|
Three Steps for Collaborating When You Can’t Read Your Co-Worker’s Poker FaceAllbiopro2018-11-07T08:46:59+09:0011월 7th, 2018|
